Erlotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has demonstrated efficacy in NSCLC patients with sensitizing mutations (14). Here, EGFR is linked to non-small cell lung carcinoma.